Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 5/20 | 0.55 |
| ▸ | HTR6 | P50406 | 10/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534950 | 0.90 | HTR1B (0.53) | HTR1BHTR6BCHEHTR1DSLC6A4 | |
| SCHEMBL3533040 | 0.89 | SLC6A4 (0.54) | HTR1BHTR6BCHEHTR1DSLC6A4 | |
| SCHEMBL3531881 | 0.89 | HTR1B (0.47) | HTR1BHTR6BCHEAKR1B1 | |
| SCHEMBL3534073 | 0.86 | HTR1B (0.49) | HTR1BHTR6BCHEADRB2 | |
| SCHEMBL3533297 | 0.84 | AKR1B1 (0.43) | HTR1BHTR6SLC6A4HRH1AKR1B1 | |
| SCHEMBL3075998 | 0.84 | HTR1B (0.50) | HTR1BHTR6AKR1B1 | |
| SCHEMBL3533645 | 0.84 | HTR6 (0.48) | HTR1BHTR6HTR1DALDH1A1AKR1B1 | |
| SCHEMBL3534118 | 0.83 | HTR1B (0.53) | HTR1BHTR6HTR1DAKR1B1ADRB2 | |
| SCHEMBL3527968 | 0.81 | HTR6 (0.50) | HTR1BHTR6AKR1B1 | |
| Hydrochloric Acid SCHEMBL3533362 | 0.81 | HTR6 (0.49) | HTR1BHTR6AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | claimed |
| EP-1931640-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007021711-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-02-22 | — | — | WO | claimed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | claimed |
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1931640-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007021711-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | HTR6, TPH1, HTR1A | HTR1B 6/4885HTR6 1/4885BCHE 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.